102978-40-5

Basic information

• Product Name: (±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy
• Synonyms: (±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy;4-Ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione
• CAS NO: 102978-40-5
• Molecular Formula: C₁₃H₁₃NO₅
• Molecular Weight: 263.25
• Mol File: 102978-40-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 193-195℃
• Boiling Point: 666.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.50
• PKA: 11.20±0.20(Predicted)
• CAS DataBase Reference: (±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy(CAS DataBase Reference)
• NIST Chemistry Reference: (±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy(102978-40-5)
• EPA Substance Registry System: (±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy(102978-40-5)

Safety Data

• Hazardous Substances Data: 102978-40-5(Hazardous Substances Data)

Usage

General Description

The chemical "(±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy" is a heterocyclic compound with a pyranoindolizine core structure. It contains a trione functional group and a hydroxyl group, and has an ethyl substituent at the 4-position of the core structure. (±)- 1H-Pyrano[3,4-f]indolizine-3,6,10(4H)-trione, 4-ethyl-7,8-dihydro-4-hydroxy has potential biological activity and may be used in medicinal or pharmaceutical applications. Its 7,8-dihydro-4-hydroxy group suggests the presence of antioxidant properties, and its heterocyclic structure indicates possible interactions with biological receptors or enzymes. Further research and testing may reveal its specific uses and effects.

Upstream product

• 65515-33-5 6-chloro-2-methoxypyridine-3-carboxylic acid 
• 60-29-7 diethyl ether 
• 102978-41-6 4'-ethyl-1',4',7',8'-tetrahydro-4'-hydroxy-3'H,10'H-spiro[1,3-dioxolane-2,6'-pyrano[3,4-f]indolizine]-3',10'-dione 
• 128434-26-4 ethyl 2-acetoxy-2-<6-(acetylaminomethyl)-1,1-(ethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolizin-7-yl>butanoate 
• 128434-24-2 ethyl 2-acetoxy-2-<6-cyano-1,1-(ethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolizin-7-yl>butanoate 
• 128434-23-1 ethyl acetoxy-<6-cyano-1,1-(ethylenedioxy)-5-oxo-1,2,3,5-tetrahydroindolizin-7-yl>acetate 
• 110714-43-7 ethyl 2-bromo-2-(6′-cyano-5′-oxo-3′,5′-dihydro-2′H-spiro[[1,3]dioxolane-2,1′-indolizine]-7′-yl)acetate 
• 58610-65-4 ethyl 2-(6′-cyan-5′-oxo-3′,5′-dihydro-2′H-spiro[[1,3]dioxolane-2,1′-indolizine]-7′-yl)acetate 
• 145474-08-4 4-ethyl-3,10-dioxo-1H,3H,4H,6H,7H,8H,10H-pyrano[3,4-f]indolizine-5-carboxylic acid methyl ester 
• 145474-07-3 methyl 7-[1-(methoxycarbonyl)propyl]-5-oxo-1,2,3,5-tetrahydroindolizine-8-carboxylate 
• 145474-06-2 methyl 7-methoxycarbonylmethyl-5-oxo-1,2,3,5-tetrahydroindolizine-8-carboxylate 
• 120461-65-6 dimethyl 3-chloro-2-pentenedioate 
• 43083-10-9 4-ethyl-1,6,7,8-tetrahydro-10H-pyrano[3,4-f]indolizine-3,10(4H)-dione 
• 73427-97-1 6-(acetoxymethyl)-1,1'-(ethylenedioxy)-7-<1'-(ethoxycarbonyl)propyl>-5-oxo-Δ⁶⁽⁸⁾-tetrahydroindolizine 

Downstream Products

• 104195-62-2 10-amino-(20RS)-camptothecin 
• 86639-52-3 7-ethyl-10-hydroxycamptothecin 
• 100286-90-6 irinotecan hydrochloirde 
• 130144-34-2 4,11-diethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione 
• 7689-03-4 camptothecin 
• 130194-92-2 9-hydroxy-(20RS)-camptothecin 
• 130194-90-0 9-amino-(20RS)-camptothecin 
• 31456-25-4 camptothecin 
• 256411-95-7 C₃₈H₄₂N₄O₈ 
• 256411-94-6 C₃₇H₃₉N₃O₈ 
• 256411-93-5 C₃₆H₃₇N₃O₈ 
• 256411-89-9 C₃₅H₃₅N₃O₈ 
• 256411-73-1 C₃₅H₃₅N₃O₈ 
• 256411-74-2 C₃₆H₃₇N₃O₈ 

Relevant articles and documents

Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: Total synthesis and biological activity

-

Preparation method of three-membered ring compound

The invention discloses a preparation method of a three-membered ring compound. The compound is an important intermediate for preparing racemic camptothecin compounds. The method comprises the following steps of: taking 6-chlorine-2-methoxy nicotinic acid as an initial raw material, and reacting the 6-chlorine-2-methoxy nicotinic acid with 1-pentene-3-ketone and a lithium reagent to obtain a lactone compound; reducing lactone to obtain a diol compound; oxidizing the diol compound to obtain a hemiacetal compound; oxidizing the hemiacetal compound to obtain a lactone compound; inserting carbonylinto the lactone compound to obtain a 6-position n-propyl ester compound; demethylating the n-propyl ester compound to form a pyridone compound; and finally, reacting the pyridone compound with tert-butyl acrylate, and decarboxylating to obtain the three-membered ring compound, namely 4-ethyl-4-hydroxyl-7, 8-dihydro-1H-pyrano [3, 4-f] indolizine-3, 6, 10 (4H)-triketone. The method is high in yield, short in synthesis route, simple and cheap in raw materials and easy in purification.

Hexa-cyclic camptothecin derivatives

A novel hexa-cyclic compound, a derivative of camptothecin, of the general formula: STR1 The compound is prepared from an aminoketone compound and a pyranoindolizine compound through Friedlaender reaction. It has an excellent antitumor activity and a high